Design, synthesis, and biological evaluation of novel biphenyl-4-carboxamide derivatives as orally available TRPV1 antagonists
作者:Hiromasa Oka、Koichi Yonezawa、Akio Kamikawa、Kazuhiro Ikegai、Norio Asai、Shohei Shirakami、Satoshi Miyamoto、Toshihiro Watanabe、Tetsuo Kiso、Yukihiro Takemoto、Seiji Tamura、Takahiro Kuramochi
DOI:10.1016/j.bmc.2018.06.001
日期:2018.7
A new series of transient receptor potential vanilloid type 1 (TRPV1) antagonists were designed and synthesized from N-(3-hydroxyphenyl)-2-(piperidin-1-ylmethyl)biphenyl-4-carboxamide hydrochloride (8). SAR studies identified (R)-N-(1-methyl-2-oxo-1,2,3,4-tetrahydro-7-quinolyl)-2-[(2-methylpyrrolidin-1-yl)methyl]biphenyl-4-carboxamide hydrochloride (ASP8370, 7), as a compound with high aqueous solubility
从N-(3-羟苯基)-2-(哌啶-1-基-甲基)联苯-4-甲酰胺盐酸盐(8)设计并合成了一系列新的瞬态受体电位香草酸1型(TRPV1)拮抗剂。SAR研究确定了(R)-N-(1-甲基-2-氧代-1,2,3,4-四氢-7-喹啉基)-2-[((2-甲基吡咯烷-1-基)甲基]联苯-4甲酰胺盐酸盐(ASP8370,7),是一种具有高水溶性的化合物,在人肝微粒体中具有令人满意的稳定性,并降低了CYP3A4的抑制作用。选择ASP8370作为对神经性疼痛有明显改善作用的临床开发候选药物。SAR研究还揭示了TRPV1拮抗作用与激动作用之间转换的潜在机制。